High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Rea, D; Legros, L; Raffoux, E; Thomas, X; Turlure, P; Maury, S; Dupriez, B; Pigneux, A; Choufi, B; Reman, O; Stéphane, D; Royer, B; Vigier, M; Ojeda-Uribe, M; Recher, C; Dombret, H; Huguet, F; Rousselot, P

Rea, D; Legros, L; Raffoux, E; Thomas, X; Turlure, P; Maury, S; Dupriez, B; Pigneux, A; Choufi, B; Reman, O; Stéphane, D; Royer, B; Vigier, M; Ojeda-Uribe, M; Recher, C; Dombret, H; Huguet, F; Rousselot, P.

Affiliation

Rea D; Service d'Hématologie Clinique, Hôpital Saint-Louis, Paris, France.

Leukemia ; 20(3): 400-3, 2006 Mar.

Article in En | MEDLINE | ID: mdl-16437142

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Blast Crisis/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Benzamides; Dexamethasone/administration & dosage; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Pilot Projects; Piperazines/administration & dosage; Pyrimidines/administration & dosage; Vincristine/administration & dosage

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Combined Chemotherapy Protocols / Blast Crisis / Precursor Cell Lymphoblastic Leukemia-Lymphoma Limits: Humans Language: En Journal: Leukemia Year: 2006 Document type: Article

Search on Google

XML

PubMed Links